免疫干预新策略的研究进展及展望
|
摘要
免疫干预的策略主要包括免疫预防和免疫治疗。免疫干预和免疫治疗的研究在近年均取得了突出的进展,在疾病预防和治疗中发挥越来越重要的作用。本文结合2018年国家自然科学基金委员会免疫干预新策略论坛,从免疫预防、免疫治疗、重大疾病免疫干预新策略等方面,概述了我国免疫干预新策略的研究现状和所面临的挑战。
Strategies for Immune intervention,mainly including immune prevention and immue therapy.The field of immune intervention has made remarkable progress in recent years,thus playing an increasingly important role in disease prevention and treatment.Based on the forum of new strategy of immune intervention organized by National Natural Science Foundation of China(NSFC),this review summarizes the current research status,and future challenge in China.
Strategies for Immune intervention,mainly including immune prevention and immue therapy.The field of immune intervention has made remarkable progress in recent years,thus playing an increasingly important role in disease prevention and treatment.Based on the forum of new strategy of immune intervention organized by National Natural Science Foundation of China(NSFC),this review summarizes the current research status,and future challenge in China.
引文
[1] Li YX, Yin ZD, Shao ZJ, et al. Population-based Surveillance for Bacterial Meningitis in China,September2006-December 2009.Emerging Infectious Diseases,2014,20(1):61—69.
[2] Gupta N,Garg S,Vedi S,et al.Future Path Toward TB Vaccine Development:Boosting BCG or Re-educating by a New Subunit Vaccine.Frontiers Immunology,2018,9.doi:ARTN 2371.10.3389/fimmu.2018.02371(2018).
[3] RodrIguez E,Schetters ST.T,van Kooyk Yvette.The tumour glyco-code as a novel immune checkpoint for immunotherapy.Nature Reviews Immunology,2018,18(3):204—211.
[4] Tubiana M.The role of immunotherapy in the treatment of cancer.Bulletin De L Academie Nationale Medecine,1992,176(6):859—866.
[5] June CH,OConnor RS,Kawalekar OU,et al.CAR T cell immunotherapy for human cancer.Science.2018,359(6382):1361—1365.
[6] Croft M,Siegel RM.Beyond TNF:TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Nature Reviews Rheumatology,2017,13(4):217—233.
[7] Bird L. Calming the cytokine storm. Nature Reviews Immunology,2018,18(7):417.
[8] June CH,Sadelain M.Chimeric Antigen Receptor Therapy.The New England Journal of Medicine,2018,379:64—73.
[9] Ellebrecht CT,Bhoj VG,Nace A,et al.Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.Science,2016,353(6295):179—184.
[10]Sedykh SE,Prinz VV,Buneva VN,et al. Bispecific antibodies:design,therapy,perspectives. Drug Design Development and Therapy,2018,12:195—208.
[11]Buque A,Bloy N,Aranda F,et al.Trial Watch-Small moleculestargetingtheimmunologicaltumor microenvironment for cancer therapy. Oncoimmunology,2016,5(6),doi:ARTN e1149674.10.1080/2162402X.2016.1149674(2016).
[12]Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382):1350—1355.
[13]Jain T,Sun T,Durand S,et al.Biophysical properties of the clinical-stage antibody landscape. Proceedings of National Academy of Sciences of The United States of America,2017,114(5):944—949.
[14] Hu FP,Guo Y,Zhu DM,et al.Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance,2005—2014.Clincal Microbiology and Infection,2016,22:S9—S14.
[15]Deane KD,El-Gabalawy H.Pathogenesis and prevention of rheumatic disease:focus on preclinical RA and SLE.Nature Reviews Rheumatology,2014,10(4):212—228.
[16]Zhang X,Zhang DY,Jia HJ,et al.The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment.Nature Medicine,2015,21(8):895—905.
[17] Weisshaar S,Zeitlinger M.Vaccines Targeting PCSK9:A Promising Alternative to Passive Immunization with MonoclonalAntibodiesintheManagementof Hyperlipidaemia?Drugs,2018,78(8):799—808.
[18]Nakagami H, Morishita R. Therapeutic Vaccines for Hypertension:a New Option for Clinical Practice.Current Hypertension Reports,2018,20(3),doi:ARTN 22 10.1007/s11906-018-0820-z(2018).
[19]Rajendran L,Paolicelli RC. Microglia-Mediated Synapse Loss in Alzheimers Disease.Journal of Neuroscience,2018,38(12):2911—2919.
[20] Herline K, DrummondE, WisniewskiT. Recent advancementstowardtherapeuticvaccinesagainst Alzheimers disease.Expert Review of Vaccines,2018,17(8):707—721.
[21]Lanzavecchia A,Fruhwirth A,Perez L,et al.Antibodyguided vaccine design:identification of protective epitopes.Current Opinion in Immunology,2016,41:62—67.
[22]Crowe JE.Principles of Broad and Potent Antiviral Human Antibodies:Insights for Vaccine Design.Cell Host&Microbe,2017,22(2):193—206.
[23]Xia YF,Wu J,Wei W,et al.Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination.Nature Materials,2018,17(2):187—+.
[24]van Kasteren SI,Neefjes J,Ovaa H.Creating molecules thatmodulateimmuneresponses. NatureReviews Chemistry,2018,2(8):184—193.
[25]Shi JJ, Kantoff PW, Wooster R, et al. Cancer nanomedicine:progress, challenges and opportunities.Nature Reviews Cancer,2017,17(1):20—37.
[26]Zhao M,Zhang HJ,Liu KF,et al.Human T-cell immunity against the emerging and re-emerging viruses.Science ChinaLife Sciences,2017,60(12):1307—1316.
[27]Bouvier NM. The Future of Influenza Vaccines:A Historical and Clinical Perspective.Vaccines-Basel,2018,6(3),doi:ARTN 58 10.3390/vaccines6030058(2018).
[28]Pavlakis GN,Felber BK.A new step towards an HIV/AIDS vaccine.Lancet,2018,392(10143):192—194.
[29]Graham BS,Sullivan NJ.Emerging viral diseases from a vaccinology perspective:preparing for the next pandemic.Nature Immunology,2018,19(1):20—28.
[2] Gupta N,Garg S,Vedi S,et al.Future Path Toward TB Vaccine Development:Boosting BCG or Re-educating by a New Subunit Vaccine.Frontiers Immunology,2018,9.doi:ARTN 2371.10.3389/fimmu.2018.02371(2018).
[3] RodrIguez E,Schetters ST.T,van Kooyk Yvette.The tumour glyco-code as a novel immune checkpoint for immunotherapy.Nature Reviews Immunology,2018,18(3):204—211.
[4] Tubiana M.The role of immunotherapy in the treatment of cancer.Bulletin De L Academie Nationale Medecine,1992,176(6):859—866.
[5] June CH,OConnor RS,Kawalekar OU,et al.CAR T cell immunotherapy for human cancer.Science.2018,359(6382):1361—1365.
[6] Croft M,Siegel RM.Beyond TNF:TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Nature Reviews Rheumatology,2017,13(4):217—233.
[7] Bird L. Calming the cytokine storm. Nature Reviews Immunology,2018,18(7):417.
[8] June CH,Sadelain M.Chimeric Antigen Receptor Therapy.The New England Journal of Medicine,2018,379:64—73.
[9] Ellebrecht CT,Bhoj VG,Nace A,et al.Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.Science,2016,353(6295):179—184.
[10]Sedykh SE,Prinz VV,Buneva VN,et al. Bispecific antibodies:design,therapy,perspectives. Drug Design Development and Therapy,2018,12:195—208.
[11]Buque A,Bloy N,Aranda F,et al.Trial Watch-Small moleculestargetingtheimmunologicaltumor microenvironment for cancer therapy. Oncoimmunology,2016,5(6),doi:ARTN e1149674.10.1080/2162402X.2016.1149674(2016).
[12]Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science, 2018, 359(6382):1350—1355.
[13]Jain T,Sun T,Durand S,et al.Biophysical properties of the clinical-stage antibody landscape. Proceedings of National Academy of Sciences of The United States of America,2017,114(5):944—949.
[14] Hu FP,Guo Y,Zhu DM,et al.Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance,2005—2014.Clincal Microbiology and Infection,2016,22:S9—S14.
[15]Deane KD,El-Gabalawy H.Pathogenesis and prevention of rheumatic disease:focus on preclinical RA and SLE.Nature Reviews Rheumatology,2014,10(4):212—228.
[16]Zhang X,Zhang DY,Jia HJ,et al.The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment.Nature Medicine,2015,21(8):895—905.
[17] Weisshaar S,Zeitlinger M.Vaccines Targeting PCSK9:A Promising Alternative to Passive Immunization with MonoclonalAntibodiesintheManagementof Hyperlipidaemia?Drugs,2018,78(8):799—808.
[18]Nakagami H, Morishita R. Therapeutic Vaccines for Hypertension:a New Option for Clinical Practice.Current Hypertension Reports,2018,20(3),doi:ARTN 22 10.1007/s11906-018-0820-z(2018).
[19]Rajendran L,Paolicelli RC. Microglia-Mediated Synapse Loss in Alzheimers Disease.Journal of Neuroscience,2018,38(12):2911—2919.
[20] Herline K, DrummondE, WisniewskiT. Recent advancementstowardtherapeuticvaccinesagainst Alzheimers disease.Expert Review of Vaccines,2018,17(8):707—721.
[21]Lanzavecchia A,Fruhwirth A,Perez L,et al.Antibodyguided vaccine design:identification of protective epitopes.Current Opinion in Immunology,2016,41:62—67.
[22]Crowe JE.Principles of Broad and Potent Antiviral Human Antibodies:Insights for Vaccine Design.Cell Host&Microbe,2017,22(2):193—206.
[23]Xia YF,Wu J,Wei W,et al.Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination.Nature Materials,2018,17(2):187—+.
[24]van Kasteren SI,Neefjes J,Ovaa H.Creating molecules thatmodulateimmuneresponses. NatureReviews Chemistry,2018,2(8):184—193.
[25]Shi JJ, Kantoff PW, Wooster R, et al. Cancer nanomedicine:progress, challenges and opportunities.Nature Reviews Cancer,2017,17(1):20—37.
[26]Zhao M,Zhang HJ,Liu KF,et al.Human T-cell immunity against the emerging and re-emerging viruses.Science ChinaLife Sciences,2017,60(12):1307—1316.
[27]Bouvier NM. The Future of Influenza Vaccines:A Historical and Clinical Perspective.Vaccines-Basel,2018,6(3),doi:ARTN 58 10.3390/vaccines6030058(2018).
[28]Pavlakis GN,Felber BK.A new step towards an HIV/AIDS vaccine.Lancet,2018,392(10143):192—194.
[29]Graham BS,Sullivan NJ.Emerging viral diseases from a vaccinology perspective:preparing for the next pandemic.Nature Immunology,2018,19(1):20—28.